Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 5,000 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph Lyssikatos sold 5,000 shares of the company’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $16.84, for a total transaction of $84,200.00. Following the transaction, the insider owned 897,688 shares in the company, valued at $15,117,065.92. The trade was a 0.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Enliven Therapeutics Trading Down 7.8%

Shares of NASDAQ:ELVN traded down $1.40 during trading on Tuesday, hitting $16.53. 889,495 shares of the stock were exchanged, compared to its average volume of 455,920. The company has a market cap of $981.06 million, a PE ratio of -8.98 and a beta of 0.35. The company has a fifty day moving average price of $20.35 and a two-hundred day moving average price of $20.35. Enliven Therapeutics, Inc. has a 12-month low of $13.30 and a 12-month high of $25.37.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.11. Equities research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Enliven Therapeutics has an average rating of “Moderate Buy” and an average price target of $41.00.

Hedge Funds Weigh In On Enliven Therapeutics

A number of institutional investors have recently modified their holdings of the company. Invesco Ltd. boosted its position in Enliven Therapeutics by 4.3% during the second quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock worth $440,000 after acquiring an additional 913 shares during the last quarter. BNP Paribas Financial Markets grew its position in shares of Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares during the period. Quantbot Technologies LP increased its stake in Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after purchasing an additional 1,434 shares during the last quarter. Legal & General Group Plc boosted its stake in Enliven Therapeutics by 4.8% in the 3rd quarter. Legal & General Group Plc now owns 33,765 shares of the company’s stock worth $691,000 after buying an additional 1,540 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Enliven Therapeutics by 8.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock worth $428,000 after buying an additional 1,693 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.